Incorporating newer agents in the treatment of acute myeloid leukemia.

Authors :: Raj RV
Abedin SM
Atallah E
Source :: Leukemia research [Leuk Res] 2018 Nov; Vol. 74, pp. 113-120. Date of Electronic Publication: 2018 Oct 19.
Publication Year :: 2018
Abstract: Prognosis for patients with AML remains dismal. Despite multiple clinical trials across several decades, little improvement for the therapy of non-APL AML was noted. However, over the last couple of years, several new therapies have demonstrated efficacy in the therapy of patients with AML. Several of those have been approved by the FDA for AML therapy. These include CPX-351, midostaurin, gemtuzumab ozogamicin, enasidenib and ivosidenib. Our goal in this review is to summarize currently available data on these new therapies and discuss the rapidly evolving treatment landscape of AML.<br /> (Copyright © 2018 Elsevier Ltd. All rights reserved.)